Filing Details
- Accession Number:
- 0001209191-17-059815
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-11-08 17:29:32
- Reporting Period:
- 2017-11-01
- Accepted Time:
- 2017-11-08 17:29:32
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1131324 | Genomic Health Inc | GHDX | Services-Medical Laboratories (8071) | 770552594 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1649689 | J James Vaughn | 301 Penobscot Drive Redwood City CA 94063 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-11-01 | 2,410 | $17.33 | 32,195 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2017-11-01 | 1,497 | $17.33 | 33,692 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-11-01 | 2,410 | $32.57 | 31,282 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-11-01 | 1,497 | $32.58 | 29,785 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-11-01 | 1,710 | $32.59 | 28,075 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2017-11-02 | 824 | $17.33 | 28,899 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2017-11-02 | 100 | $17.33 | 28,999 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-11-02 | 824 | $32.51 | 28,175 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-11-02 | 100 | $32.50 | 28,075 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-11-02 | 455 | $32.51 | 27,620 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2017-11-01 | 2,410 | $0.00 | 0 | $17.33 |
Common Stock | Employee Stock Option (right to buy) | Disposition | 2017-11-01 | 1,497 | $0.00 | 0 | $17.33 |
Common Stock | Employee Stock Option (right to buy) | Disposition | 2017-11-02 | 824 | $0.00 | 0 | $17.33 |
Common Stock | Employee Stock Option (right to buy) | Disposition | 2017-11-02 | 100 | $0.00 | 0 | $17.33 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
4,590 | 2018-12-04 | No | 4 | M | Direct | |
3,093 | 2018-12-04 | No | 4 | M | Direct | |
2,269 | 2018-12-04 | No | 4 | M | Direct | |
2,169 | 2018-12-04 | No | 4 | M | Direct |
Footnotes
- Includes an aggregate of 17,374 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 8, 2017.
- Represents weighted average sale price. Actual sale prices ranged from $32.50 to $32.79.
- Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- Represents weighted average sale price. Actual sale prices ranged from $32.50 to $32.68.
- Represents weighted average sale price. Actual sale prices ranged from $32.50 to $32.85.
- Represents weighted average sale price. Actual sale prices ranged from $32.50 to $32.57.
- Represents actual sale price.
- Represents weighted average sale price. Actual sale prices ranged from $32.50 to $32.54.
- The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.